title: [Desensitization to trimethoprim-sulfamethoxazole in patients with HIV infection].
abstract: OBJECTIVE
  To evaluate the safety and efficacy of an in-patient oral desensitization regimen in HIV- infected patients hypersensitive to trimethoprim-sulfamethoxazole (TMP-SMX).
  
  
  METHODS
  TMP-SMX was given orally once a day using incremental doses every day, starting with 0.4 mg TMP/2 mg SMX at day 4 and achieving a full dosage of TMP-SMX (80 mg/400 mg) at day 5. Success was defined as clinical tolerance of the final dose for more than 10 days following completion of the procedure.
  
  
  RESULTS
  Desensitization was successfully completed in 29 of 30 patients. A transient rash occurred in one patient during desensitization and resolved without need for discontinuation of the desensitization protocol. The procedure failed in one patient who experienced sustained moderate cutaneous reaction with fever on day 5.
  
  
  CONCLUSIONS
  Our results suggest the safety and efficacy of an inpatient oral desensitization regimen in 30 HIV-infected patients who had experienced cutaneous reactions to trimethoprim-sulfamethoxazole (TMP-SMX). Specific desensitization to TMP-SMX allows to circumvent the limitations towards effective prophylaxis of PCP that are dependent on the occurrence of cutaneous reactions to the drug.
authors.affiliation: Service d'Immunologie Clinique, Hôpital Broussais, Paris.
authors.forename: C
authors.initials: C
authors.lastname: Piketty
authors.forename: J
authors.initials: J
authors.lastname: Gilqouin
authors.forename: M
authors.initials: M
authors.lastname: Kazatchkine
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003888:Desensitization, Immunologic; D003875:Drug Eruptions / Q000517:prevention & control*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination